Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 18, Issue 23, 2000, Pages 3946-3951

  Fujiwaki, Ritsuto ^a   Hata, Kohkichi ^a   Nakayama, Kentaro ^a   Fukumoto, Manabu ^a   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034548797     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.23.3946     Document Type: Article

References (32)

1. Kinetic studies of thymidine phosphorylase from mouse liver
2. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis
3. Pyrimidine metabolism-enzymatic pathways of uracil and thymidine degradation
4. Beta-amino acid formation by tissue slices incubated with pyrimidines
5. Enzymes of uracil catabolism in normal and neoplastic human tissues
6. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate
7. Dihydrouracil dehydrogenase activity in normal, differentiating and regenerating liver and hepatomas
8. Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors
9. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase
10. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
11. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy
12. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours
13. Quantitation of dihydropyrimidine dehydrogenase in tumor specimens of patients treated with 5-fluorouracil using quantitative polymerase chain reaction assay
14. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice
15. Angiogenic factor
16. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor
17. Thymidine phosphorylase is angiogenic and promotes tumor growth
18. Angiogenic activity of enzymes
19. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase
20. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
21. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers
22. Association of thymidine phosphorylase concentration with ultrasound-derived indices of blood flow in ovarian masses
23. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer
24. Changes in definitions of clinical staging for carcinoma of the cervix and ovary
25. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer
26. Catabolism of exogenously supplied thymidine to thymine and dihydrothymine by platelets in human peripheral blood
27. Thymidine phosphorylase expression in progression of cervical cancer: Correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis
28. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers
29. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo
30. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
31. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer